Mesa Gains Advanced Vein Care as UVVC Expands Arizona Footprint

📊 Key Data
  • 40% of American adults affected by chronic venous insufficiency (CVI)
  • Mesa's population exceeds 500,000, indicating a large potential patient base
  • UVVC operates over 50 clinics across six states
🎯 Expert Consensus

Experts would likely conclude that UVVC's expansion into Mesa addresses a critical gap in specialized vascular care, offering advanced, minimally invasive treatments that improve accessibility and patient outcomes in the East Valley.

2 months ago

Mesa Gains Advanced Vein Care as UVVC Expands Arizona Footprint

MESA, AZ – February 17, 2026 – United Vein & Vascular Centers (UVVC), a prominent national provider of specialized vascular care, officially opened the doors to its newest clinic today in Mesa, significantly expanding access to advanced, minimally invasive treatments for residents across the East Valley.

The new facility, located at 6118 E. Brown Rd., is the company's sixth in the greater Phoenix area and marks a continued strategic investment in Arizona's healthcare landscape. It aims to provide relief for thousands of individuals suffering from often painful and progressive vein and vascular conditions.

Addressing a Growing Need in the East Valley

The expansion into Mesa comes as data reveals a substantial underlying need for specialized vascular services in the region. Chronic venous insufficiency (CVI), a condition where leg veins struggle to send blood back to the heart, affects as many as 40% of American adults. With Mesa's population exceeding 500,000, this suggests a vast number of residents may be living with symptoms ranging from cosmetic varicose veins to more severe issues like leg pain, swelling, and non-healing ulcers.

Cardiovascular diseases, which encompass a wide range of vascular disorders, remain a leading cause of mortality and morbidity in Arizona. The high prevalence of these conditions underscores the importance of accessible, specialized care centers that can offer early diagnosis and effective treatment, potentially preventing more serious complications down the line. While several vein clinics operate in the East Valley, UVVC's entry into Mesa adds a significant new option for patients in communities from Gilbert and Fountain Hills to Apache Junction, particularly within a state that has faced challenges with healthcare access and a documented shortage of physicians.

The outpatient model offered by the new clinic provides a crucial alternative to traditional hospital-based procedures. By focusing exclusively on vascular issues, these centers can deliver highly specialized care with greater convenience and efficiency, a model that is becoming increasingly vital for meeting the demands of an aging population and alleviating pressure on overburdened hospital systems.

A National Strategy for Specialized Outpatient Care

The Mesa opening is a key part of United Vein & Vascular Centers' broader national growth strategy. Founded in 2015, the Florida-based company has rapidly grown to operate over 50 clinics across six states, establishing itself as a leader in the outpatient vascular care sector. The company's model focuses on identifying key regional markets with demonstrated demand and establishing state-of-the-art facilities staffed by board-certified specialists.

This approach reflects a larger trend in the U.S. healthcare industry toward specialized, ambulatory clinics. These centers offer a more focused and patient-centric experience for specific conditions, often at a lower cost and with greater convenience than a full-service hospital. By concentrating expertise and technology on a single area of medicine, companies like UVVC can achieve high-quality outcomes while streamlining the patient journey from consultation to recovery.

The Mesa clinic is poised to compete in a market with established providers, including the Center for Vein Restoration and other local practices. UVVC's expansion suggests confidence in its results-driven care model and its ability to attract patients seeking the latest treatment options and personalized care plans.

The Forefront of Minimally Invasive Vein Treatment

At the heart of the new clinic's mission is a suite of advanced, minimally invasive procedures designed to treat vascular conditions with less pain and faster recovery times than traditional surgeries like vein stripping. The clinic will be led by Dr. Amanda Dao, D.O., a board-certified physician specializing in these modern techniques.

Patients at the Mesa facility will have access to a range of treatments tailored to their specific diagnosis and health goals, including:

  • Radiofrequency Ablation (RFA): A procedure that uses gentle heat delivered through a tiny catheter to close down diseased veins, rerouting blood flow to healthier vessels.

  • VenaSeal™ Closure System: An innovative treatment that uses a proprietary medical-grade adhesive to seal off problematic veins, often allowing patients to return to normal activities almost immediately.

  • Varithena®: A non-thermal microfoam that is injected into the vein, causing it to collapse. The body then naturally absorbs the treated vein.

  • Microphlebectomy: The targeted removal of large, bulging varicose veins through tiny incisions that typically do not require stitches and leave minimal scarring.

  • Sclerotherapy: A long-standing and effective treatment, primarily for spider veins and smaller varicose veins, where a solution is injected to close the affected vessels.

These technologies represent a significant leap forward in vascular care, transforming treatments that once required a hospital stay and lengthy recovery into simple outpatient procedures. By offering these options, UVVC aims to not only alleviate the physical symptoms of vein disease but also improve the overall quality of life for patients, restoring their comfort, mobility, and confidence.

The opening of the Mesa clinic provides a new and vital resource for East Valley residents, combining a proven national healthcare model with the latest medical innovations to address a widespread and often undertreated health concern.

Product: Pharmaceuticals & Therapeutics
Metric: Financial Performance
Theme: ESG
Event: IPO
Sector: Financial Services Hospitals & Health Systems
UAID: 16316